Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Voacamine is a naturally occurring dimeric indole alkaloid of the secologanin type, found in several plants including Voacanga africana and Tabernaemontana divaricata. It is isolated from the bark of Pescheria fuchsiae folia and has been approved as an antimalarial drug in several African countries. Voacamine exhibits antagonistic activity at the cannabinoid receptor 1 (CB1) and acts as an inhibitor of P-glycoprotein (ABCB1), which is involved in multidrug resistance in tumor cells. It has also been identified as a potential inhibitor of epidermal growth factor receptor (EGFR), showing antiproliferative effects on certain cancer cell lines. Voacamine is under investigation for its ability to modulate multidrug resistance, particularly by sensitizing resistant tumor cells to chemotherapeutics like doxorubicin, without significant toxicity to normal fibroblasts at relevant concentrations[1][2][4][5][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on voacamine.